Helix Biopharma (HBPCF) Stock Price, News & Analysis

Company Overview

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Key Stats

• Today's Range: $0.60 to $0.60
• 50-Day Range: $0.45 to $0.60
• 52-Week Range: $0.59 to $0.60
• Volume: N/A
• Average Volume: 1 shs
• Market Capitalization: $31.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HBPCF Stock Analysis - Frequently Asked Questions

How have HBPCF shares performed this year?

Helix Biopharma's stock was trading at $0.4549 on January 1st, 2025. Since then, HBPCF shares have increased by 31.9% and is now trading at $0.60.
View the best growth stocks for 2025 here.

How were Helix Biopharma's earnings last quarter?

Helix Biopharma Corp. (OTCMKTS:HBPCF) released its quarterly earnings data on Monday, June, 16th. The company reported ($0.02) EPS for the quarter.

How do I buy shares of Helix Biopharma?

Shares of HBPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 6/16/2025
• Today: 6/18/2025
• Fiscal Year End: 7/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED-BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:HBPCF
• CIK: N/A
• Web: www.helixbiopharma.com
• Phone: 905-841-2300
• Fax: 905-841-2244
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.82 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -694.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.99
• Quick Ratio: 0.99

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 53,020,000
• Free Float: 48,992,000
• Market Cap: $31.81 million
• Optionable: Not Optionable
• Beta: -0.15